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ProteinKnee pain is commonly seen in orthopedic and rehabilitation outpatient clinical settings, and in the aging popula-
tion. Bursitis of the knee joint, especially when the volume of the synovial ﬂuid is large enough, can compress
and distend the nearby soft tissues, causing pain in the knee joint. Out of all the bursae surrounding the knee
joint, supra-patellar bursitis is most often associated with knee pain. Treatment strategies in managing supra-
patellar bursitis include the aspiration of joint synovial ﬂuid and then followed by steroid injection into the bursa.
When supra-patellar bursitis is caused by degenerative disorders, the concept of viscosupplementation treatment
may be effective by injecting hyaluronic acid into the bursa. However, the rheology or the changes in the concentra-
tions of proteins (biomarkers) that are related to the development of bursitis in the synovial ﬂuid is virtually unex-
plored. Therefore, this study aimed to identify the concentration changes in the synovial ﬂuid total protein amount
and individual proteins associatedwith supra-patellar bursitis using the Bradford protein assay andwestern immu-
noglobulin methods. A total of 20 patients were divided into two groupswith 10 patients in each group. One group
received the high molecular weight hyaluronic acid product of Synvisc Hylan G-F 20 and the other group received
the lowmolecular weight hyaluronic acid product of Hya-Joint Synovial Fluid Supplement once per week injection
into the bursa for a total of 3 weeks. Signiﬁcant decreases in the synovial ﬂuid total protein concentrationswere ob-
served after the seconddosage of highmolecularweight hyaluronic acid injections. ApolipoproteinA-I, interleukin 1
beta, alpha 1 antitrypsin, andmatrixmetalloproteinase 1 proteins revealed a trend of decreasingwestern immuno-
blotting band densities after hyaluronic acid injections. The decreases in apolipoprotein A-I and interleukin 1 beta
protein band densities were signiﬁcant in the highmolecular weight hyaluronic acid injection group. Transthyretin,
complement 5, andmatrilin 3 proteins revealed a trend of increasing western immunoblotting band densities after
hyaluronic acid injections. Transthyretin revealed signiﬁcant increases in protein banddensities in both thehigh and
low molecular weight hyaluronic acid injection groups. This study may provide the rationale for targeting several
biomarkers associated with lipid transport, inﬂammation, and anti-aging as possible disease modifying therapies
for the treatment of supra-patellar bursitis and even degenerative joint disorders.
© 2014 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Knee pain is a common complaint in orthopedic and rehabilitation
outpatient clinical settings. Bursitis of the knee joint, especially whenl Medicine & Rehabilitation,
ueishan, Taoyuan County 333,
. Open access under CC BY-NC-ND licethe volume of the synovial ﬂuid is large enough, can compress and dis-
tend the nearby soft tissues, causing pain in the knee joint (de Miguel
Mendieta et al., 2006). Common clinical symptoms include local joint
pain, stiffness, as well as possible burning pain. Patients suffering from
supra-patellar bursitis may have trouble standing, and in performing
activities such as standing, walking, squatting and running (Hill et al.,
2001). Joint stiffness can also occur the next day after waking up from
sleep (Hill et al., 2001).
There are several bursae surrounding the knee joint. These bursae
include the supra-patellar bursa, also known as the supra-patellar
pouch, infra-patellar bursa, bursa at the pes anserinus, and at the popli-
teal fossa area (e.g. Baker's cyst) (de Miguel Mendieta et al., 2006). Thense.
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femur and communicates with the synovial cavity of the knee (Marra
et al., 2008). Bursae are synovium-lined structures usually not easily
detected by any imaging method. Bursitis can be detected using
arthrography, soft tissue musculoskeletal ultrasound, and can also be
seen on routine magnetic resonance imaging (MRI) scans (Hayashi
et al., 2010). Inﬂammation of the bursa or bursitis will result in
a cystic-like appearance due to accumulation of the ﬂuid within
the bursa and thickening of the synovial membrane (Beaman and
Peterson, 2007).
Out of all the bursae surrounding the knee joint, supra-patellar
bursitis is most often associated with knee pain. Supra-patellar bursitis
is signiﬁcantly correlated with knee pain when soft tissue ultrasound
measures a 2 millimeter (mm) distention of the bursa due to the
presence of increased synovial ﬂuid (SF) volume (de Miguel Mendieta
et al., 2006). The cause of bursitis can be associated with inﬂammatory
or degenerative arthritis (such as knee OA), infection, and malignancy
(Hayashi et al., 2010). Osteoarthritis (OA) remains to be the frequent
cause of supra-patellar bursitis as synovitis is a common manifestation
observed in knee OA (Hedbom and Hauselmann, 2002). It is crucial to
differentiate the causes of supra-patellar bursitis as the treatment strat-
egy is different. For bursa that is infected, further investigation is needed
as well as the initiation of antibiotic therapy (Aaron et al., 2011).
The most often performed treatment strategy in managing supra-
patellar bursitis is the aspiration of joint SF followed by steroid injection
into thebursa. Although reports have shown that the injection of steroid
can increase the walking distance in patients with bursitis as compared
with patientswhodid not receive the steroid treatment, themechanism
behind the treatment effectiveness of steroid remains controversial
(Leung et al., 2011). The concept of viscosupplementation has been
widely practiced clinically in the treatment of knee OA (Cohen et al.,
2008). Viscosupplementation is a therapeutic modality based on the
replacement of SF with a hyaluronic acid (HA) solution (Balazs, 2004).
Based on our clinical experience, injecting HA solution into the supra-
patellar bursa after aspiration can offer longer lasting analgesic effects
and effectively reduce the volume of SF as compared with other treat-
ment options such as oral non-steroid anti-inﬂammatory drugs, appli-
cation of physical modality onto the affected knee joint, and steroid
injection in a higher number of patients (Leung et al., 2011).
Most of the up-to-date studies related to intra-articular (IA) HA
injections focus mainly on the regulation and expression of interleukin
(IL) and tumor necrosis factor-alpha in ﬁbroblast-like synoviocytes
(Huang et al., 2011). The regulations or the changes in the concentra-
tions of proteins (biomarkers) that are related to the development of
bursitis remain virtually unexplored. In this study, laboratory tech-
niques of protein assay and western immunoblotting will be used.
Proteins that revealed signiﬁcant concentration differences before and
after HA injections on 2-dimensional electrophoresis (2-DE) gel analy-
ses will be further validated using western immunoblotting. After the
completion of this study, we hypothesize that there will be signiﬁcant
changes in the protein concentrations that are related to inﬂammation
and oxidation. We hope that the results obtained in this study may
help in the future development of novel treatment options for patients
with supra-patellar bursitis, such as protein supplementation or devel-
oping chelating agents against certain biomarkers.
2. Materials and methods
2.1. Subjects
In this study, a total of 20 patients diagnosed with supra-patellar
bursitis on the unilateral knee were recruited. The inclusion criteria
were:
1. The thickness of the supra-patellar bursa was greater than 2 mm as
conﬁrmed by musculoskeletal ultrasound. Ultrasound has alsoconﬁrmed that the supra-patellar bursa is in communication with
the synovial cavity of the knee joint.
2. The volume of the synovial ﬂuid (SF) in the supra-patellar bursa was
the cause of pain in the knee joint.
3. The injection of hyaluronic acid (HA) into the bursa resulted in the
reduction of SF volume and in the alleviation of pain for the patient.
4. Patient has received steroid injections, oral nonsteroidal anti-
inﬂammatory drugs (NSAIDs), and physical modality treatments
(e.g. shortwave diathermy and interferential wave) but without
reduction in SF volume and the alleviation of joint pain.
5. Themajor cause of suprapatellar bursitis is due to degenerative knee
disorder (e.g. knee OA) or causes other than infectious and inﬂam-
matory knee disorders.
Exclusion criteria included patients with history of a metal knee
implant, pregnancy, severe degeneration of knee joints with total oblit-
eration of joint space, joint and chicken or egg allergy (Tang et al., 2005).
Patients with isolated supra-patellar bursa mass mistakenly diagnosed
as bursitis was not enrolled in this study. The aspirated SF prior to HA
injections was sent for SF analysis. SF showing evidences of crystals
suggesting possible gouty arthritis and infection was excluded from
the study. All patients signed the informed consent before participating
in this study. The institutional ethics committee approved all the proto-
cols involved in this study.
2.2. Sample collection
The aspiration technique followed the standard lateral approach
with the knees extended. A strict sterilized procedure was applied to
prevent septic infection. The musculoskeletal ultrasound was used to
accurately guide the needle into the bursa for the aspiration of SF. Accu-
rate placement of the needle in the bursa avoided poking the needle
into the muscle or other soft tissues which may cause SF to be contam-
inated with blood (Chen et al., 2011a).
Each patient has different volumes of bursa ﬂuid. Asmuch SF as possi-
blewas aspirated fromthebursa. Approximately 5 to 10mLof the aspirat-
ed SFwas sent for biochemical analysisﬁrst. Samples showing evidence of
active infection or inﬂammation were not included in this study. SF
samples were centrifuged at 2500 rpm for 20 min at 4 °C. The superna-
tants were stored in 90 μl aliquots with 10 μl of a proteinase inhibitor
solution containing 100 mM EDTA (Sigma, St. Louis, MO, USA), 20 mM
N-ethylmaleimide (Sigma), and 20mMaminoethylbenzenesulfonyl ﬂuo-
ride (Sigma) added. SF samples free of infection, inﬂammation, and red
blood cells were further aliquoted and stored at −20 °C if they were
to be used for experimental analysis within one week. Otherwise the
samples were stored at−80 °C. Total protein concentration was cal-
culated for every SF sample.
2.3. Treatment protocols
The recruited 20 patients were divided into two groups with 10
patients in each group. One group received the high molecular weight
hyaluronic acid (HMW HA) product of 2 mL Synvisc Hylan G-F 20
(Genzyme Biosurgery, USA) with 6000 kDa). The other group received
the low molecular weight hyaluronic acid (LMW HA) product of 2 mL
Hya-Joint Synovial Fluid Supplement (SciVision Biotech Inc., Taiwan)
with 500–730 kDa. Patients received once per week injection treatment
into the bursa for a total of 3 weeks. Ultrasound-guided approach was
applied for accurate aspiration of bursa SF samples and the injection of
HA into the supra-patellar bursa.
2.4. The calculation of SF total protein concentrations
The standard curve of known bovine serum albumin (BSA) (Sigma,
N96% purity) concentrations (1 μg, 0.5 μg, 0.25 μg, and 0.125 μg) was
constructed to calculate the total protein concentrations of the SF. The
Table 1
Demographic data of supra-patellar bursitis patients who received low molecular weight
hyaluronic acid injections.
Age Sex Right/left knee Disease duration Previous treatment strategy
72 F Left 3 years SWD+ glucosamine + NSAID
58 M Right 6 months None
61 F Right 6 months None
59 F Right 4 months None
70 F Left 3 years IFC + glucosamine + NSAID
72 F Right 4 years SWD+ glucosamine + NSAID
76 M Left 4 years SWD+ glucosamine + NSAID
60 F Left 5 months Glucosamine
57 M Right 10 months None
53 F Left 10 months None
M: Male.
F: Female.
SWD: Shortwave diathermy.
IFC: Interferential wave.
NSAID: Nonsteroidal anti-inﬂammatory drugs.
Table 2
Demographic data of supra-patellar bursitis patients who received highmolecular weight
hyaluronic acid injections.
Age Sex Right/left knee Disease duration Previous Treatment Strategy
60 M Right 1 year None
70 M Right 4 years SWD+ glucosamine + NSAID
58 M Right 6 months None
57 F Right 6 months Glucosamine
73 F Left 5 years Glucosamine + NSAID
70 M Left 10 months SWD+ IFC + glucosamine
66 F Right 6 months None
60 F Right 6 months None
59 F Left 1 year None
75 F Left 3 years SWD+ glucosamine + NSAID
M: Male.
F: Female.
SWD: Shortwave diathermy.
IFC: Interferential wave.
NSAID: Nonsteroidal anti-inﬂammatory drugs.
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tions (da Silva and Arruda, 2006). The Bio-Rad Protein Assay dye
reagent was used. The dye-proteins were measured by Unicam UV1
spectrophotometer at an absorbance of 595 nm. The SF samples were
diluted 30 times ﬁrst by ddH2O in order to ﬁt into the linear BSA stan-
dard curve for protein concentration calculation.
2.5. Western immunoblotting
In this study, the western immunoblotting method was used to
detect the percentage of protein concentration differences before and
after the completion of HA injections. Antibodies against the SF proteins
that may be associated with degenerative joint diseases such as OA
(both polyclonal and monoclonal) were purchased from the ABCAM
company (ABCAM, Cambridge, MA, USA). Primary Antibodies to detect
the following proteins were purchased: apolipoprotein A-I, transthyretin
(TTR), interleukin 1 beta (IL-1 Beta), alpha 1 antitrypsin, matrilin 3, com-
plement 5 (C5), matrix metalloproteinase 1 (MMP1), and prostaglandin
D2 synthase (PGDS). Triplicate western immunoblotting was done for
every protein.
SF samples were loaded onto the pre-casted 10% SDS-polyacrylamide
gel and were electrophoresed at 60 mV constant voltage until the dye
front was near the end. The electrophoresed protein was transferred
onto a 0.45 μm thick nitrocellulose membrane, which was saturated for
1 h with 5% (w/v) milk powder in Tris-buffered saline (TBS) containing
0.05% Tween 20 (TBS-T). Membranes were incubated with primary anti-
bodies overnight at room temperature. After washing with TBS-T, mem-
branes were incubated for 2 h with horseradish peroxidase-conjugated
secondary IgG antibodies. After the ﬁnal wash, the immune-stained
proteins were developed using the ECL developing kit (GE Healthcare
BioScience, UK), and detected by the Fluorchem M image system. The
primary mouse monoclonal anti-GAPDH antibody (Cell Signaling Tech-
nology Inc., Boston, MA, USA) was used as the internal control reference
protein bands.
In terms of image analysis, the BIORAD Quantity One 1D analytical
software was used to calculate the protein band densities. The band
volume and density are in positive correlationwith the protein concen-
tration. The higher the detected protein density, the greater the protein
concentration. Percentage increase or decrease of protein concentra-
tions was calculated from the band densities.
2.6. Data analysis
The Wilcoxon signed-rank test was used to compare the mean age
between patient groups, and the percentage changes in protein concen-
trations. The SF total protein concentrations were expressed as mean±
standard error of means (SEM). One-way ANOVAwith Tukey's post hoc
testwas used to compare themeans of SF total protein concentrations at
different time periods before and after HA injections. The Statistical
Program for Social Sciences (SPSS) version 13 (SPSS Inc., Chicago) was
used for data calculations. Values of p b 0.05 were considered statistically
signiﬁcant.
3. Results
The average age of the patients who received LMWHA injectionwas
63±8 years. The average age of thepatientswho receivedHMWHA in-
jection was 64 ± 8 years. There was no signiﬁcant statistical difference
in between the average ages. Tables 1 and 2 describe the gender, the
side of knee in which supra-patellar was diagnosed, the duration of
the disease, and the previous treatment strategies of the recruited
patients.
Protein assaywas performed tomeasure the total protein concentra-
tions in the SF samples. SF sampleswere diluted by 30 times in order for
the measured optical density (OD) values to ﬁt into the linear standard
curve of OD value versus known BSA concentrations for total proteinconcentration calculations. In the HMW HA group, total protein
concentrations in the SF samples of “1 week after 2nd HA injection”
(22.59 ± 2.16 mg/mL) and “1 week after 3rd HA injection” (22.59 ±
2.16 mg/mL)were signiﬁcantly lower as comparedwith the SF samples
of “before HA injection” (26.08 ± 2.47 mg/mL) and “1 week after the
1st HA injection” (27.33 ± 3.62 mg/mL) (p b 0.05, Table 3).
Triplicate western immunoblotting was performed to test the anti-
body–antigen reactions to the purchased proteins that may be related
to the disease process of arthritis and degenerative joint disorders.
Four proteins revealed decreases in concentrations after the completion
of HA injections. Apolipoprotein A-I, interleukin 1 beta, and alpha 1
antitrypsin proteins in the HMW HA group revealed the most obvious
percentage concentration decreases (p b 0.05, Table 4). Apolipoprotein
A-I decreased by 57% (Fig. 1A) and interleukin 1 beta by 51% after the
completion of HMWHA injections.
Three proteins showed evidence of increased concentration in the SF
after HA injections. TTR revealed signiﬁcant increases in concentrations
after the completion of both LMW and HMW HA injections (p b 0.05,
Table 4). Concentrations of complement 5 and matrilin increased by
about 19% and 16% respectively after the completion of HMWHA injec-
tions but did not reach statistical signiﬁcance.
4. Discussion
Supra-patellar bursitis is a common cause of knee swelling and pain
frequently seen in the rehabilitation and orthopedic outpatient clinical
setting (Aaron et al., 2011). If the cause of supra-patellar bursitis is
due to degenerative disorders such as knee OA, subsequent injection
Table 3
Synovial ﬂuid total protein concentrations before and after HA injections.
Before HA
injection A
1 week after 1st
HA injection B
1 week after 2nd
HA injection C
1 week after 3rd
HA injection D
Statistical
analyses
Total protein concentration of LMW
HA group in mg/mL (n = 10)
27.02 ± 3.11 25.78 ± 2.06 25.48 ± 3.09 23.88 ± 4.51 No statistical differences
between all concentrations
Total protein concentration of HMW
HA group in mg/mL (n = 10)
26.08 ± 2.47 27.33 ± 3.62 22.59 ± 2.16 20.68 ± 2.71 A VS C = p b 0.05
A VS D = p b 0.05
B VS C = p b 0.05
B VS D = p b 0.05
Values expressed as mean ± standard deviation (SD).
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preventing future development of bursa SF. The changes in the rheology
of SF after HA injection into the bursa are seldom explored.
There were no control or sham treatment groups in this study.
This was due to the fact that the proteomic analyses of SF in non-
degenerative knee joints were thoroughly documented in our previous
study (Chen et al., 2011a). As a result, the differences in the 2-DE SF
proteome maps of non-degenerative knee joints and in patients
with supra-patellar bursitis are known. Proteins associated with acute
inﬂammatory response and complement activation are shown to be
increased in the SF of supra-patellar bursitis patients (data not present-
ed). Therefore, the changes in the protein concentrations observed in
this study represent the rheological changes of SF in supra-patellar
bursitis patients after hyaluronic acid injections.
Western immunoblotting was the experimental procedure chosen
to detect the protein bands and its concentration differences. It is a
sensitive visual assay tool to detect antibody-antigen reactions, and is
the preferred method for the validation of protein concentrations after
proteomic analysis of 2-dimensional electrophoresis (2-DE) (Burnette,
2009; Chen et al., 2011b). Both LMWHA and HMWHA revealed similar
trends in the decrease and increase of the examined SF proteins after
the completion of injection treatment. It has been documented that
higher molecular weight HA may have a better anti-inﬂammatory
effect, whereas low molecular weight HA has superior efﬁcacy for
chondroprotection (Huang et al., 2010). Other studies have also
shown that hyaluronic acid is capable of slowing aging through its anti-
oxidant effect (Zhao et al., 2008). Apolipoprotein A-I revealed the most
drop (a decrease of 57%) in protein concentration after HMWHA injec-
tions. Other proteins that revealed decreases in concentration percent-
ages included interleukin 1 beta, alpha 1 antitrypsin, and matrix
metalloproteinases 1. TTR revealed signiﬁcant percentage increases in
protein concentrations after both LMW and HMW HA injections.
Other proteins that revealed increases in concentration percentages
included matrilin 3, and complement 5.
Higher apolipoprotein A-I concentrations in the SF indicates that
higher lipid levels will enter the knee joint cavity (Oliviero et al.,
2012). This will contribute to local joint inﬂammatory processes and
subsequent pain. Interleukin 1 beta protein functions as a catabolic
factor, and matrix metalloproteinases are extracellular matrix proteins
associatedwith tissue remodeling and osteochondral changes in degen-
erative joint disorders (Huang et al., 2011; Kaspiris et al., 2013). The
matrix metalloproteinase (MMP) gene family that is believed to be
closely associated with degenerative joint disorder is MMP1 (Kaspiris
et al., 2013). Both interleukin 1 beta and MMP1 proteins are proven to
be up-regulated during the progression of degenerative joint disorders
(Huang et al., 2011; Kaspiris et al., 2013). A high concentration of
alpha 1 antitrypsin protein in the SF conﬁrms the active progression of
cartilage decay and inﬂammatory process in OA (Olszewska-Slonina
et al., 2013). As a result, decreases in the concentrations of these pro-
teins highly indicate that the inﬂammatory and degenerative processes
are reduced after the completion of HA injections, with HMW HA
showing the most obvious results.
The association between TTR and degenerative joint disorders is
seldom discussed. One study that was done about 3 decades agomentioned that TTR level is decreased in the serum of patients with
active rheumatoid arthritis (Surrall et al., 1987). TTR is present in the
serum, and cerebrospinal ﬂuid (CSF) (Chen et al., 2011b). It is a carrier
of the thyroid hormone thyroxine (T4) and retinol-binding protein
(Chen et al., 2011b). TTR is associated with aging, and its ability to
bind to beta-amyloid protein is believed to be able to prevent
Alzheimer's disease (Li and Buxbaum, 2011). Interestingly, we have dis-
covered that the TTR concentration in the SF is increased after HA injec-
tions. This may suggest that increased TTR level in the SF may have a
close associationwith the anti-aging effect or alleviation of the degener-
ative process in degenerative joint diseases.
The complement system complements the ability of antibodies and
phagocytic cells to clear pathogens from an organism. Studies have
suggested that low-grade complement activation may contribute to
the development of degenerative diseases, such as macular degenera-
tion, Alzheimer's diseases, and even OA. Complement 5 (C5) is the com-
plement system believed to be associated with degenerative joint
disorders (Wang et al., 2011). Therefore, it is logical to think that the
SF concentration of C5 should decrease after HA injections. However,
results in this study indicated that the SF C5 concentrations are slightly
increased after both LMW and HMW HA injections.
Matrilin-3 (MATN3) is a skeletal-speciﬁc, tetrameric pericellular
protein, localizing to the peri-cellular matrix of chondrocytes, and has
both anti-anabolic and pro-catabolic functions. It was believed that
MATN3 may be a useful marker to diagnose OA or to evaluate the
progression of OA in the SF (Vincourt et al., 2012). Similar to C5, one
would think that the concentration of MATN3 protein should decrease
after HA injections. In fact, increases in the SF MATN3 concentrations
of approximately 10% and 16% were observed after the completion of
LMW, and HMW HA injections respectively. As a result, these ﬁndings
may indicate that SF proteins of C5 and MATN3 may not play crucial
roles or not be signiﬁcantly associated with the development of supra-
patellar bursitis.
It was evident that after the second injection dosage of HMWHA, SF
total protein concentrations signiﬁcantly decreased as compared to the
SF total protein concentration prior to HMW HA injection. In SF, about
60% to 80% of proteins are high abundant proteins such as albumin
and immunoglobulin (Chen et al., 2011a). Results in this study
have shown that the concentrations of inﬂammatory proteins such
as apolipoprotein A-I and interleukin 1 beta are greatly reduced
after HMW HA injections. This may be the likely cause of the signiﬁ-
cant decreases in SF total protein concentrations after the second
HMW HA injections.
Blood contamination in SF is a serious problem in SF peptide proﬁl-
ing due to similar peptide proﬁle between SF and blood, but withmuch
higher total protein concentrations in the serum (Chen et al., 2011a).
Therefore, SF samples were retrieved under ultrasound guidance to
avoid blood contamination. One protein that is believed to be associated
with inﬂammation and aging is prostaglandin D2 synthase (PGDS)
(Chen et al., 2009). Monoclonal antibody against human PGDS protein
was purchased to explore whether PGDS is associated with the disease
entity of supra-patellar bursitis in SF samples.However, triplicatewestern
immunoblotting analysis was not able to detect any PGDS protein bands
in SF samples.
Table 4
Percentage changes in the synovialﬂuid protein concentrations before and after LMWand
HMWHA injections.
1 week after 3rd HA
injection LMW HA Group
1 week after 3rd HA
injection HMWHA Group
Apolipoprotein A-I ↓ by 33%⁎ ↓ by 57%⁎
Interleukin 1 beta ↓ by 35%⁎ ↓ by 51%⁎
Alpha 1 antitrypsin ↓ by 16% ↓ by 37%⁎
Matrix metalloproteinase
1 (MMP1)
↓ by 13% ↓ by 21%
Transthyretin (TTR) ↑ by 20%⁎ ↑ by 44%⁎
Complement 5 (C5) ↑ by 10% ↑ by 19%
Matrilin 3 ↑ by 10% ↑ by 16%
↑: Increase in SF protein concentration.
↓: Decrease in SF protein concentration.
⁎ p b 0.05, as compared with before the hyaluronic acid injections.
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in the SF total protein and individual proteins using the Bradford protein
assay andwestern immunoglobulinmethods. After the completion of the
HA injections to the bursa, proteins associated with lipid transport and
inﬂammation (e.g. apolipoprotein A-I and interleukin 1 beta) are de-
creased. This may be the likely cause of the observed decrease in SF
total protein concentration after the seconddosage of HMWHA injection.
On the other hand, concentration of the protein with anti-aging effect
(e.g. TTR) is signiﬁcantly increased after both LMW and HMWHA injec-
tions. As a result, the rheology of SF in supra-patellar bursitis patients isFig. 1. Representative western immunoblotting protein bands. A. Western immunoblot-
ting protein bands of apolipoprotein A-I, showing a decrease in band density after HMW
HA injections. The molecular weight of apolipoprotein A-I was measured to be approxi-
mately 28 kDA. B. Western immunoblotting protein bands of TTR, showing an increase
in band density after HMW HA injections. The molecular weight of TTR was measured
to be approximately 60 kDA.changed after HA injections, with obvious concentration decreases in
inﬂammatory and lipid transport proteins, and with concentration in-
creases in anti-aging protein. Results obtained in this study may provide
the rationale for targeting several biomarkers as a diseasemodifying ther-
apy for the treatment of supra-patellar bursitis and even degenerative
joint disorders.
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